Trends of cutaneous melanoma in the netherlands: Increasing incidence rates among all breslow thickness categories and rising mortality rates since 1989

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 524-530

  Hollestein, L M ^a   van den akker, S A W ^a   Nijsten, T ^a   Karim kos, H E ^a   Coebergh, J W ^a,b   de vries, E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Netherlands Cancer Registry ^*  (Netherlands)

Author keywords

Epidemiology; Incidence; Melanoma; Mortality; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BRESLOW THICKNESS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEX DIFFERENCE; THICKNESS; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MELANOMA; MIDDLE AGED; NETHERLANDS; PROGNOSIS; REGISTRIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84856324411     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr128     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN. 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: IARC 2010.
2. Curado M, Edwards B, Shin H et al. Cancer in Five Continents. Vol. IX. Lyon, France: IARC 2007.
3. de Vries E, Schouten LJ, Visser O et al. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003; 39: 1439-1446.
4. Holterhues C, Vries E, Louwman MW et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130: 1807-1812.
5. Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol 2010; 28: 281-286.
6. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605-613.
7. Levell NJ, Beattie CC, Shuster S, Greenberg DC. Melanoma epidemic: a midsummer night's dream? Br J Dermatol 2009; 161: 630-634.
8. Fritz A, Percy C, Jack A et al. International Classification of Diseases for Oncology (ICD-O). Geneva, Switzerland: World Health Organization 2002.
9. Sobin LH, Wittekind C. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. New York, NY: Wiley 2002.
10. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-2010.
11. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23: 51-64.
12. Linos E, Swetter SM, Cockburn MG et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129: 1666-1674.
13. Marcos-Gragera R, Vilar-Coromina N, Galceran J et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol 2010; 24: 1083-1088.
14. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006; 95: 91-95.
15. Pruthi DK, Guilfoyle R, Nugent Z et al. Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. J Am Acad Dermatol 2009; 61: 44-50.
16. Whiteman DC, Bray CA, Siskind V et al. Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? Eur J Cancer Prev 2008; 17: 243-250.
17. Montella A, Gavin A, Middleton R et al. Cutaneous melanoma mortality starting to change: a study of trends in Northern Ireland. Eur J Cancer 2009; 45: 2360-2366.
18. Baumert J, Schmidt M, Giehl KA et al. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res 2009; 19: 24-30.
19. Schouten LJ, Straatman H, Kiemeney LA et al. The capture-recapture method for estimation of cancer registry completeness: a useful tool? Int J Epidemiol 1994; 23: 1111-1116.
20. Krol AD, van der Rhee HJ, Dieleman M, Welvaart K. [The 'freckle bus' campaign; an unhealthy phenomenon or a sensible experiment?] De 'sproetenbus'; een ongezond verschijnsel of een bezonnen experiment? Ned Tijdschr Geneeskd 1990; 134: 2047-2050.
21. de Vries E, van de Poll-Franse LV, Louwman WJ et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481-488.
22. Del Marmol V, de Vries E, Roseeuw D et al. A Prime minister managed to attract elderly men in a Belgian Euromelanoma campaign. Eur J Cancer 2009; 45: 1532-1534.
23. de Vries E, Houterman S, Janssen-Heijnen ML et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the southeast of The Netherlands. Ann Oncol 2007; 18: 1110-1116.
24. de Vries E, Nijsten TE, Visser O et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19: 583-589.
25. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
26. de Vries E, Karim-Kos HE, Janssen-Heijnen ML et al. Explanations for worsening cancer survival. Nat Rev Clin Oncol 2010; 7: 60-63.
27. Lens M. Sentinel lymph node biopsy in melanoma patients. J Eur Acad Dermatol Venereol 2010; 24: 1005-1012.
28. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
29. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627.
30. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
31. MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-591.
32. Haddad FF, Stall A, Messina J et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol 1999; 6: 144-149.
33. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
34. Downing A, Yu XQ, Newton-Bishop J, Forman D. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer 2008; 123: 861-866.
35. Chellini E, Crocetti E, Carli P et al. The melanoma epidemic debate: some evidence for a real phenomenon from Tuscany, Italy. Melanoma Res 2007; 17: 129-130.
36. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331: 481.